Discovery and validation of molecular biomarkers for colorectal adenomas and cancer with application to blood testing
LaPointe, Lawrence C
Pedersen, Susanne K
Brown, Glenn S
Wattchow, David Anthony
Molloy, Peter L
Public Library of Science
This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
(C) 2012 LaPointe et al.
Results: Genome-wide analysis uncovered reproducible gene expression signatures for both adenomas and cancers compared to controls. 386/489 (79%) of the adenoma and 439/529 (83%) of the adenocarcinoma biomarkers were validated in independent tissues. We also identified genes differentially expressed in adenomas compared to cancer. KIAA1199 was selected for further analysis based on consistent up-regulation in neoplasia, previous studies and its interest as an uncharacterized gene. Plasma KIAA1199 RNA levels were significantly higher in patients with either cancer or adenoma (31/ 40) compared to neoplasia-free controls (6/20).
Colorectal cancer, Biomarker validation
LaPointe, L.C., Pedersen, S.K., Dunne, R., Brown, G.S., Pimlott, L., Gaur, S., McEvoy, A., Thomas, M., Wattchow, D., Molloy, P.L. and Young, G.P., 2012. Discovery and validation of molecular biomarkers for colorectal adenomas and cancer with application to blood testing. PLoS ONE 7(1): e29059.